| 1 |
34708562 | HER2-Targeted, Degradable Core Cross-Linked Micelles for Specific and Dual pH-Sensitive DOX Release. | 2022 Jan |
2 |
| 2 |
34749055 | Novel doxorubicin / folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: In-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment. | 2022 Jan |
1 |
| 3 |
34896567 | A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer. | 2022 Jan 25 |
2 |
| 4 |
34931757 | Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy. | 2022 Feb |
4 |
| 5 |
34940773 | Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER+, PR+ or HER2+ breast cancer. | 2022 Jan 19 |
1 |
| 6 |
35385034 | Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer. | 2022 Apr 4 |
2 |
| 7 |
35524907 | microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation. | 2022 Jul |
1 |
| 8 |
35531104 | Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial. | 2022 Apr |
1 |
| 9 |
33613693 | Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. | 2021 |
1 |
| 10 |
33718207 | The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis. | 2021 |
3 |
| 11 |
33828191 | Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. | 2021 Apr 7 |
2 |
| 12 |
33929622 | Microwave-Assisted Chitosan-Functionalized Graphene Oxide as Controlled Intracellular Drug Delivery Nanosystem for Synergistic Antitumour Activity. | 2021 Apr 30 |
1 |
| 13 |
33937091 | Erratum: The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis. | 2021 |
1 |
| 14 |
34094901 | The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer. | 2021 |
2 |
| 15 |
34119547 | Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. | 2021 Aug 1 |
1 |
| 16 |
34166713 | An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. | 2021 Sep 1 |
2 |
| 17 |
34572735 | Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance. | 2021 Sep 7 |
1 |
| 18 |
34812802 | A dimeric α-helical cell penetrating peptide mounted with an HER2-selective affibody. | 2021 Nov 23 |
1 |
| 19 |
34826322 | A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. | 2021 Dec 21 |
2 |
| 20 |
34900939 | Ferritin Conjugates With Multiple Clickable Amino Acids Encoded by C-Terminal Engineered Pyrrolysyl-tRNA Synthetase. | 2021 |
3 |
| 21 |
34944997 | Anticancer Activity of Ω-6 Fatty Acids through Increased 4-HNE in Breast Cancer Cells. | 2021 Dec 20 |
2 |
| 22 |
31134823 | Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2+ breast cancer. | 2020 Feb |
1 |
| 23 |
31883395 | Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. | 2020 May |
2 |
| 24 |
32272178 | Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. | 2020 Jul 1 |
1 |
| 25 |
32378049 | Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells. | 2020 Oct |
4 |
| 26 |
32417267 | Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. | 2020 Jul 15 |
2 |
| 27 |
32458631 | Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells. | 2020 May 1 |
3 |
| 28 |
32501121 | Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. | 2020 Aug |
1 |
| 29 |
32515640 | Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer. | 2020 Sep |
5 |
| 30 |
32696338 | Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment. | 2020 Jul 21 |
5 |
| 31 |
32946931 | Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer. | 2020 Oct |
1 |
| 32 |
32986377 | Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNFα Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells. | 2020 Sep 1 |
1 |
| 33 |
33299647 | Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. | 2020 Nov 15 |
1 |
| 34 |
33328545 | Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer. | 2020 Dec 16 |
1 |
| 35 |
29621912 | Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin. | 2019 Mar |
2 |
| 36 |
30314995 | HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way. | 2019 Mar 29 |
2 |
| 37 |
30624616 | Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. | 2019 Jun 1 |
1 |
| 38 |
30654182 | Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment. | 2019 Apr |
4 |
| 39 |
31067739 | Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin. | 2019 May 7 |
1 |
| 40 |
31213813 | A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. | 2019 |
10 |
| 41 |
31239670 | Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer. | 2019 |
8 |
| 42 |
31251311 | Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. | 2019 Aug 1 |
2 |
| 43 |
31294107 | Doxorubicin loaded carboxymethyl Assam bora rice starch coated superparamagnetic iron oxide nanoparticles as potential antitumor cargo. | 2019 Jun |
2 |
| 44 |
31521263 | Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. | 2019 Dec 1 |
2 |
| 45 |
31632008 | Erratum: Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]. | 2019 |
1 |
| 46 |
29280210 | Genetically Engineered Liposome-like Nanovesicles as Active Targeted Transport Platform. | 2018 Feb |
1 |
| 47 |
29408424 | A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system. | 2018 May 10 |
5 |
| 48 |
29434871 | Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. | 2018 Feb |
2 |
| 49 |
29464058 | Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity. | 2018 Jan 19 |
5 |
| 50 |
29518137 | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. | 2018 |
4 |